About

Dr. Amie J. Goodin is an Assistant Professor within the Department of Pharmaceutical Outcomes and Policy (POP) and the Center for Drug Evaluation and Safety (CoDES) at the University of Florida College of Pharmacy. She holds a Doctor of Philosophy degree from the University of Kentucky’s Martin School of Public Policy, with a specialization in pharmaceutical outcomes and a Certificate in Informatics, as well as a Master of Public Policy from the University of Kentucky. Her postdoctoral fellowship at UF POP focused on pharmacoepidemiology methods and health services research. Her research incorporates mixed-method approaches to assess the impact of policy changes on treatment access and utilization for Substance Use Disorders, particularly among Medicaid enrollees and pregnant women. Dr. Goodin is the lead for the Health Services Research track within POP's graduate program and serves as the faculty lead for Research Strategy within the Consortium for Medical Marijuana Clinical Outcomes Research. Her work emphasizes health policy, health disparities, vulnerable populations, maternal and child health, and substance use disorders. She has been featured in media outlets such as the New York Times and has contributed to research on opioid use reduction and psychiatric hospital quality measures.

Research topics

• Medicine
• Family medicine
• Psychiatry
• Internal medicine
• Political Science
• Demography
• Nursing
• Emergency medicine
• Psychology
• Pathology
• Pharmacology
• Environmental health
• Anesthesia

Selected publications

• <scp> Δ ⁸ </scp> ‐tetrahydrocannabinol, <scp> Δ ⁹ </scp> ‐tetrahydrocannabinol, and cannabidiol carboxylic acid metabolites in authentic meconium samples

  Journal of Forensic Sciences · 2026-04-12

  article

  Abstract The consumption of cannabis‐related products during pregnancy is increasing. Marijuana (cannabis) use during pregnancy, whether for nonmedical or medical purposes to relieve of pregnancy‐related symptoms and discomfort, can lead to potential adverse clinical and neurodevelopmental outcomes for the developing fetus. Testing conventional matrices, such as blood and urine, provides information regarding the recent intake of drugs, whereas analysis of alternative specimens, such as meconium, provides information regarding maternal use and potential in utero exposure during the third trimester of pregnancy. In this study, meconium samples ( n = 19) were obtained from neonates at birth delivered at the University of Florida (UF). All the mothers participating in the study completed a questionnaire regarding cannabis and cannabidiol (CBD) use during pregnancy. Maternal urine samples were also collected during each trimester of pregnancy and at delivery. 11‐nor‐Δ 9 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 9 ‐THC‐COOH), 11‐nor‐Δ 8 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 8 ‐THC‐COOH) and 7‐carboxy cannabidiol (7‐COOH‐CBD) were quantitated in the meconium samples utilizing liquid chromatography‐tandem mass spectrometry (LC–MS/MS). The most frequently identified analyte was Δ 9 ‐THC‐COOH (median concentration: 113 ng/g) which was quantitated in the meconium samples ( n = 12) of neonates born to mothers who self‐reported cannabis use during the third trimester. Δ 8 ‐THC‐COOH was observed in five of the Δ 9 ‐THC‐COOH positive samples (median concentration: 15.7 ng/g). Meconium of neonates born to mothers who did not self‐report a history of cannabis use (control subjects) was negative for Δ 8 ‐THC‐COOH and Δ 9 ‐THC‐COOH. These data support further study of drug use patterns during pregnancy to focus on the clinical consequences of use during the perinatal period.

  PublisherDOI

• Effect of a Smartphone Health Application on Clinic Attendance and Acute Care Utilization Across Racial Groups [ID 3532]

  Obstetrics and Gynecology · 2026-04-30

  article
  PublisherDOI

• Are Participants Enrolled in a Postpartum Monitoring Application More Likely to Attend a Clinic Visit During the First Six Weeks Postpartum? [ID 3442]

  Obstetrics and Gynecology · 2026-04-30

  article
  PublisherDOI

• Protocol for Monitoring Postpartum Hypertension Outcomes via a Smartphone App (MOMitor): Ecological Momentary Assessment

  JMIR Research Protocols · 2026-05-22

  articleOpen accessSenior author

  Background: Postpartum hypertension defined as elevated blood pressure after childbirth, affects approximately 20% of women after delivery. Digital health interventions that include remote monitoring therefore, present an important opportunity to facilitate regular blood pressure assessment in this high-risk population. Objective: The primary objective is to assess within- and between-person changes in hypertension status over the first 6 weeks postpartum using a smartphone-based ecological momentary assessment protocol. The secondary objective is to characterize the trajectory of hypertension indicators across the 6-week period and to compare hypertension screening results from week one and week six within participants. Methods: This study uses a time-series design using data from prospectively enrolled patients within a large health system. Patients eligible for recruitment were women aged 18 years or older who spoke English, owned a smartphone, had a liveborn neonate, and were willing to download an app and respond to survey questions within the app. Throughout the study period, all participants received hypertension screening items that asked whether their blood pressure was greater than 140/90 mm Hg and whether they felt dizzy or lightheaded, short of breath, or had a severe headache. A subset of participants were additionally asked to report their blood pressure readings. We estimate within- and between-participant effects using a generalized linear mixed model for a positive hypertension screen during weeks one through six. The model includes both fixed and random effects, controlling for age, race, marital status, education, insurance status, mode of delivery, total number of pregnancies, and history of diabetes mellitus. Results: The study was funded July 2021 and data collection was initiated in November 2021. Data collection for this study, per protocol, was completed in June 2025, though other participants continue to be enrolled in the ongoing parent study. Data analysis is expected to be completed by Spring 2026 with publication planned for Summer 2026. Conclusions: The study findings will provide insight into trajectories of hypertension outcomes in postpartum women and the utility for smartphone app-based remote blood pressure monitoring among postpartum women whose blood pressure was regularly tracked. Findings will provide evidence to support whether widespread implementation of this digital health surveillance approach to improve outcomes in maternal health, especially in the postpartum period, is clinically warranted.

  PublisherDOI

• Curriculum in Pharmacoepidemiology Training Programs: A Cross‐Sectional Study to Assess Educational Needs and Alignment With Core Competencies

  Pharmacoepidemiology and Drug Safety · 2026-03-26

  articleOpen access1st authorCorresponding

  PURPOSE: Pharmacoepidemiology is a key discipline for evidence-based decision-making, yet its educational programs have not been systematically assessed for alignment with international core competencies. Our objectives were to evaluate curricula alignment of pharmacoepidemiology training programs with ISPE-recommended core competency themes and identify key curriculum content development areas. METHODS: The ISPE Core Competencies Workgroup and ISPE leadership developed a curriculum and needs assessment survey, incorporating feedback from global members. The survey was electronically distributed to leaders of pharmacoepidemiology training programs (e.g., department chairs and program directors) using the ISPE contact database, followed by snowball sampling to enhance representation. Institutional respondent characteristics were categorized by sector and geographic region. Competency mapping identified the most and least represented competency categories within curricula. Needs assessment responses were reported as proportions, and free-text responses were thematically analyzed, allowing for multiple themes per response. RESULTS: Sixty-four institutions participated (73.4% academic programs, 18.8% industry/consulting, and 7.8% government/regulatory). Representation by global region was: 35.9% Europe, 29.7% North America, 23.4% Latin America, 7.8% Asia, 1.6% Africa, and 1.6% Gulf Region. Respondents prioritized developing standards in pharmacoepidemiology training curriculum in two areas-45.5% "Epidemiology" and 36.4% "Statistics, Analysis, and Data Science"-with few endorsements of other areas. The most represented competencies covered in curricula were "Statistics" (100%, 45/45) and "Study Design" (100%, 43/43). The least represented were "Advanced Modeling" (54%, 25/46) and "Professional Practice" (66%, 31/47). Key needs in pharmacoepidemiology curriculum centered around four themes: 33.3% (8/24) "Methods (generally)", 33.3% (8/24) "Analytical Skills," 16.7% (4/24) "Communication (writing, teaching)," and 25.0% "(6/24) Other (applications, new therapies)." Content type that would best support curriculum development, as ranked by 42 respondents, was: "Learning objectives with pre-packaged activities" 45.2% (19/42), "Recorded webinars/lectures" 28.6% (12/42), "Example syllabi" 21.4% (9/42), and "Reading lists" 4.8% (2/42). CONCLUSIONS: This global assessment highlights critical gaps in pharmacoepidemiology training, particularly in advanced analytical methods and professional practice. ISPE has a unique opportunity to address these gaps by developing targeted educational activities and resources that enhance methodological rigor and practical skills.

  PublisherDOI

• Is Postpartum Depression Diagnosed More Frequently in Specific Racial and Ethnic Groups That Participated in Smartphone Application-Delivered Mental Health Screenings? [ID 1420]

  Obstetrics and Gynecology · 2025-05-15

  articleSenior author

  INTRODUCTION: Incidence of postpartum depression (PPD) varies among women of different racial and ethnic backgrounds. The opportunity for mental health screening apps to improve care quality through increased clinician–patient communication within these groups remains largely unexplored. This study investigates whether participation in MOMitor, a health screening smartphone application, is associated with increased PPD diagnosis among women of specific racial groups. METHODS: This cross-sectional, descriptive study analyzed electronic health records from MOMitor, where women reported their physical and mental health status during the 6 weeks after delivery. Charts from 2021 to 2023 were reviewed retrospectively. Incident PDD diagnosis, excluding women with prior depression history, was the outcome. The self-reported race identity groups analyzed included Black (n=193), White (n=421), Asian (n=34), American Indian/Native Alaskan/Native Hawaiian (AI/NA/H; n=33), and other and multiple races (n=162). Proportions of PPD were calculated for groups, and chi-squared analysis assessed differences in PPD distribution. RESULTS: Of the 911 patients reviewed, 68 were excluded due to prior depression history or missing race, resulting in n=843. Sixteen of 193 (8.2%) Black race, 35 of 421 (9.1%) White, 3 of 34 (8.8%) Asian, 3 of 33 AI/NA/H (9.1%), and 12 of 162 (7.4%) other and multiple races had a PPD diagnosis, resulting in non-statistically significant PPD distribution differences across groups ( P =.99). CONCLUSIONS/IMPLICATIONS: Although PPD incidence in digital health intervention participants was lower than national PPD prevalence, there was equitable distribution of diagnoses across self-identified racial identities. This may reflect the effectiveness of recent obstetricians’ inclusive educational initiatives and improved evaluation practices that have encouraged women to share their symptoms openly.

  PublisherDOI

• Does a Diagnosis of COVID-19 in Pregnancy Increase the Risk of Postpartum Mood Disorders? [ID 1430]

  Obstetrics and Gynecology · 2025-05-15

  articleSenior author

  INTRODUCTION: The relationship between COVID-19 infection in pregnancy and postpartum mental health is unclear. This study examines whether the incidence of postpartum mood disorders is increased in women diagnosed with COVID-19 in pregnancy in comparison to those without infections. METHODS: The study design is a cross-sectional, descriptive analysis of participants previously enrolled in a health intervention, MOMitor, a smartphone application, which screened physical and mental health 6 weeks after delivery discharge. Charts were reviewed retrospectively for MOMitor participants from 2021 to 2023. The primary outcome of interest was a diagnosis of depression (PPD) and/or anxiety (PPA) within 6 weeks postpartum. The independent variable was COVID-19 diagnosis during pregnancy. Exclusion criteria was prior history of depression or anxiety. Proportions of those with PPD and PPA were compared between those with and without COVID-19 during pregnancy, and values of P were calculated via chi-squared analysis to assess statistical significance. RESULTS: Nine hundred eleven participant charts were reviewed, and 664 remained once exclusion criteria were applied. Among the 150 (22.6%) who were diagnosed with COVID-19 during pregnancy, 6 (4%) developed PPD, 5 (3.3%) developed PPA, and 4 developed both mood disorders (2.7%). The P values for the comparison of PPD and PPA were both &lt;0.001, indicating that COVID-19 infection in pregnancy was associated with fewer PPD and PPA diagnoses. CONCLUSIONS/IMPLICATIONS: COVID-19 infections in pregnancy were counterintuitively associated with fewer postpartum mood disorders. This may be due to less access or desire to obtain COVID testing in the comparison group. Timely postpartum mood disorder screenings are universally recommended regardless of infection history.

  PublisherDOI

• Willingness of pregnant and postpartum women who use marijuana and/or cannabidiol to participate with their offspring in long-term cohort studies: an exploratory study

  Frontiers in Psychiatry · 2025-10-21

  articleOpen access

  Background: Prevalence of marijuana and cannabinoid use is increasing among reproductive-age women. There are uncertainties regarding long-term impacts of marijuana and/or cannabinoid exposure among pregnant women and their offspring. Longitudinal cohort studies of marijuana and/or cannabinoid exposed mother-infant dyads is the best way to ascertain the long-term impacts. However, previous studies have shown enrollment, and long-term retention are challenging in substance-exposed women. Objectives: This study explores the willingness of pregnant and postpartum women who use marijuana and/or cannabidiol to participate with their offspring in long-term cohort studies. Methods: We conducted 4 focus group discussions and one individual one-on-one interview with a total of 17 pregnant or postpartum women using an IRB approved interview guide. All interviews were audiotaped, transcribed and analyzed using the computer assisted qualitative data analysis software Atlas ti™. We used a deductive content analysis approach and utilized consensus coding procedures. Results: Marijuana and/or cannabinoid-exposed pregnant women are willing to participate in long-term research studies with their babies if they can build a trusting relationship with the research staff and are confident of their anonymity, as protection from negative consequences was a key concern. They would also like to understand in detail what type of data are collected, when and who all will see it and what will be done with the data before they provide the consent. All participants agreed that incentives are important and had various suggestions regarding the type and frequency of incentivization. Conclusion: The concerns and needs of marijuana and/or cannabinoid-exposed pregnant women recruited for research should be considered carefully in designing study protocols.

  PublisherOA PDFDOI

• Perception of Risks of Cannabis and Cannabidiol Use during Pregnancy: A Multi-Methods Study

  Medical Cannabis and Cannabinoids · 2025-06-11 · 2 citations

  articleOpen access1st authorCorresponding

  Introduction: The American College of Obstetrics and Gynecology advises against cannabis and cannabidiol (CBD) product use during pregnancy; despite this, recent studies suggest cannabis and CBD use is increasing during pregnancy. The objective of this study is to assess risk perceptions of cannabis and CBD use during pregnancy among pregnant and non-pregnant patients. Methods: The study design is multi-method; a cross-sectional survey assessing use behaviors and risk perceptions is supplemented with qualitative focus group discussions (FGDs). Recruitment for surveys was from outpatient obstetrics clinics and recruitment for FGDs was from the same clinics and a substance-use treatment clinic, from October 2022 to February 2023. The survey instrument was developed via combining question items from validated instruments that assess cannabis and CBD use and risk perceptions. Comparisons of response frequency distributions for pregnant versus non-pregnant participants were calculated with chi-square analysis for individual risk perception question items. Data from the FGDs were coded and analyzed via a deductive content analysis approach. Results: There were 261 survey respondents and 5 FGDs (n = 17). Of the surveys, 198 (75.9%) were currently pregnant, 55 (21.1%) were not pregnant, and 8 (3.1%) did not disclose pregnancy status. Approximately 5.0% (n = 13) reported currently breastfeeding. For the question, “How risky is it to use marijuana [cannabis] once or twice a week during pregnancy?”, pregnant versus non-pregnant participants responded most frequently with “great risk” (29.2% vs. 27.3%) and “not sure” (40.0% vs. 34.5%), where p = 0.88 (not significant) between pregnant vs. non-pregnant response distribution. For the question, “How risky is it to use CBD once or twice a week during pregnancy?” pregnant vs. non-pregnant participants responded most frequently with: “great risk” (22.1% vs. 20.0%), and “not sure” (52.3% vs. 41.8%), where p = 0.12 (not significant). Ever use of cannabis and CBD differed in pregnant versus non-pregnant patients (cannabis 36.0% pregnant vs. 65.5% non-pregnant; CBD 19.9% pregnant vs. 38.2% non-pregnant). Qualitative findings indicated that participants perceived that legalization of marijuana has resulted in reduction of stigma against users, but participants expressed mixed feelings toward the perception of marijuana safety due to legalization, though several participants described perceived benefits of marijuana use more generally. Conclusion: Findings indicate uncertainty of risk related to cannabis and CBD use during pregnancy regardless of current pregnancy or lactation status, despite prevalent ever use of cannabis and CBD in those who were pregnant. This suggests an urgent need for clearer risk communication about cannabis and CBD use in pregnancy.

  PublisherOA PDFDOI

• Nationwide Prevalence of Cannabidiol Use in Pregnancy and in Women of Reproductive Age

  Obstetrics and Gynecology · 2025-12-04

  articleSenior author

  Clinical guidelines recommend avoiding cannabinoids, including cannabidiol (CBD), during pregnancy and lactation. Use of CBD is widespread, but prevalence in pregnancy and among women of reproductive age is not well documented. We conducted a cross-sectional analysis using data from the 2022 and 2023 National Survey on Drug Use and Health, with incorporation of survey sampling weights to estimate the prevalence of CBD use. Similar proportions of pregnant women and reproductive-aged women reported ever using CBD in 2022 (353.4 vs 365.1, respectively) and in 2023 (323.4 [95% CI, 259.2-387.6] vs 361.3 [95% CI, 353.6-367.0], respectively) per 1,000 population. More reproductive-aged women had used CBD within the past 30 days compared with pregnant women in 2022 (121.3 vs 43.9, respectively) and in 2023 (113.2 [95% CI, 107.4-118.9] vs 39.3 [95% CI, 16.2-62.4], respectively) per 1,000 population. Due to unknown effects of CBD during pregnancy and prevalent use, clinicians should screen for CBD use to facilitate counseling patients against use in pregnancy and while breastfeeding.

  PublisherDOI

Frequent coauthors

• Joshua D. Brown

  Center for Drug Evaluation and Research

  156 shared

• Scott Martin Vouri

  Center for Drug Evaluation and Research

  69 shared

• Almut G. Winterstein

  Center for Drug Evaluation and Research

  63 shared

• Juan M. Hincapie‐Castillo

  University of North Carolina at Chapel Hill

  62 shared

• Brianna Costales

  Kaiser Permanente

  49 shared

• Sebastian Jugl

  Center for Drug Evaluation and Research

  38 shared

• Dikea Roussos‐Ross

  Florida College

  38 shared

• Ruba Sajdeya

  University of Florida

  31 shared

Education

• Ph.D., Public Policy

  University of Kentucky

  2015

• M.A., Public Policy

  University of Kentucky

• Other

  University of Kentucky